Enanta Pharmaceuticals (ENTA) Q3 2024 Annual Earnings
ENTA·Reported November 25, 2024·Before market open
Enanta Pharmaceuticals reported Q3 2024 revenue of $67.6M, beat analyst consensus of $17.9M by $49.7M. Diluted EPS came in at $-1.36, missed the $-1.16 consensus by $0.20.
Revenue
$67.6Mbeat by $49.7M
Consensus: $17.9MDiluted EPS
$-1.36missed by $0.20
Consensus: $-1.16
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Enanta Pharmaceuticals's Q3 2024 earnings report.
Enanta Pharmaceuticals (ENTA) reported Q3 2024 earnings on November 25, 2024 before market open.
Enanta Pharmaceuticals reported revenue of $67.6M and diluted EPS of $-1.36 for Q3 2024.
Revenue beat the consensus estimate of $17.9M by $49.7M. EPS missed the consensus estimate of $-1.16 by $0.20.
You can read the 10-K periodic report (0000950170-24-131260) directly on SEC EDGAR. The filing index links above go to sec.gov.